WuXi Biologics' Suzhou Facility Earns Fourth EMA GMP Certification for 19 Biologics — WuXi Biologics

Event summary

WuXi Biologics' Suzhou Biosafety Testing Center received its fourth EMA GMP certification with zero critical findings.
The certification supports EU marketing authorization for 19 biologics products from 13 clients.
Products span modalities including antibodies, enzymes, and fusion proteins developed on WuXi's integrated platform.
The inspection covered quality management, facilities, testing methods, and data integrity over four days.
WuXi's Biosafety Testing Center has enabled over 1,700 IND or BLA applications as of December 2025.

The big picture

This certification reinforces WuXi Biologics' position as a key player in the biologics contract manufacturing space, particularly for European market access. The company's ability to consistently meet EMA standards while expanding its client portfolio demonstrates both technical capability and regulatory agility. With over 982 integrated client projects as of April 2026, WuXi continues to scale its operations while maintaining quality across complex modalities.

What we're watching

Regulatory Expansion: Whether WuXi can maintain this certification pace across its global network of facilities.
Client Dependence: The concentration risk posed by enabling 19 products for just 13 clients in this certification round.
Competitive Positioning: How this certification strengthens WuXi's position against other global CRDMOs in the European market.